The impact of tacrolimus on the immunopathogenesis of staphylococcal enterotoxin-induced systemic inflammatory response syndrome and pneumonia

Microbes and Infection

Volumn 14, Issue 6, 2012, Pages 528-536

  Tilahun, Ashenafi Y ^a   Karau, Melissa J ^a   Clark, Chad R ^a   Patel, Robin ^a   Rajagopalan, Govindarajan ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemokines; Cytokines; HLA class II transgenic mice; Rodents; T lymphocytes

Indexed keywords

HLA DR3 ANTIGEN; STAPHYLOCOCCUS ENTEROTOXIN; SUPERANTIGEN; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; DRUG EFFICACY; ENTEROPATHY; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; LYMPHOCYTE PROLIFERATION; MORTALITY; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T LYMPHOCYTE ACTIVATION; TOXIC SHOCK SYNDROME;

ANIMALS; CYTOKINES; ENTEROTOXINS; HLA-DR3 ANTIGEN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; PNEUMONIA, STAPHYLOCOCCAL; STAPHYLOCOCCUS AUREUS; SUPERANTIGENS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; T-LYMPHOCYTES; TACROLIMUS; TREATMENT OUTCOME;

MUS; MUS MUSCULUS; RODENTIA; STAPHYLOCOCCUS AUREUS;

EID: 84860431073     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2012.01.001     Document Type: Article

References (49)

1. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339:520-532.
2. Baba T., Takeuchi F., Kuroda M., Yuzawa H., Aoki K.-i., Oguchi A., Nagai Y., Iwama N., Asano K., Naimi T., Kuroda H., Cui L., Yamamoto K., Hiramatsu K. Genome and virulence determinants of high virulence community-acquired mrsa. The Lancet 2002, 359:1819-1827.
3. Li M., Cheung G.Y.C., Hu J., Wang D., Joo H.Ä., DeLeo F.R., Otto M. Comparative analysis of virulence and toxin expression of global community associated methicillin resistant Staphylococcus aureus strains. J. Infect. Dis. 2010, 202:1866-1876.
4. Otto M. Basis of virulence in community-associated methicillin-resistant Staphylococcus aureus. Annu. Rev. Microbiol. 2010, 64:143-162.
5. Li H., Llera A., Malchiodi E.L., Mariuzza R.A. The structural basis of t cell activation by superantigens. Annu. Rev. Immunol. 1999, 17:435-466.
6. Cardona I.D., Cho S.H., Leung D.Y. Role of bacterial superantigens in atopic dermatitis: implications for future therapeutic strategies. Am. J. Clin. Dermatol. 2006, 7:273-279.
7. Leung D.Y. Atopic dermatitis and the immune system: the role of superantigens and bacteria. J. Am. Acad. Dermatol. 2001, 45:S13-S16.
8. Dinges M.M., Orwin P.M., Schlievert P.M. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev. 2000, 13:16-34.
9. Proft T., Fraser J.D. Bacterial superantigens. Clin. Exp. Immunol. 2003, 133:299-306.
10. DeVries A.S., Lesher L., Schlievert P.M., Rogers T., Villaume L.G., Danila R., Lynfield R. Staphylococcal toxic shock syndrome 2000-2006: epidemiology, clinical features, and molecular characteristics. PLoS ONE 2011, 6:e22997.
11. Schlievert P.M. Cytolysins, superantigens, and pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 2009, 200:676-678.
12. Soares M.J., Tokumaru-Miyazaki N.H., Noleto A.L., Figueiredo A.M. Enterotoxin production by Staphylococcus aureus clones and detection of brazilian epidemic mrsa clone (iii::B:A) among isolates from food handlers. J. Med. Microbiol. 1997, 46:214-221.
13. Strandberg K.L., Rotschafer J.H., Vetter S.M., Buonpane R.A., Kranz D.M., Schlievert P.M. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J. Infect. Dis. 2010, 202:1690-1697.
14. Rajagopalan G., Iijima K., Singh M., Kita H., Patel R., David C.S. Intranasal exposure to bacterial superantigens induces airway inflammation in HLA class ii transgenic mice. Infect. Immun. 2006, 74:1284-1296.
15. Roy C.J., Warfield K.L., Welcher B.C., Gonzales R.F., Larsen T., Hanson J., David C.S., Krakauer T., Bavari S. Human leukocyte antigen-dq8 transgenic mice: a model to examine the toxicity of aerosolized staphylococcal enterotoxin B. Infect. Immun. 2005, 73:2452-2460.
16. Wilson G.J., Seo K.S., Cartwright R.A., Connelley T., Chuang-Smith O.N., Merriman J.A., Guinane C.M., Park J.Y., Bohach G.A., Schlievert P.M., Morrison W.I., Fitzgerald J.R. A novel core genome-encoded superantigen contributes to lethality of community-associated mrsa necrotizing pneumonia. PLoS Pathog. 2011, 7:e1002271.
17. John C.C., Niermann M., Sharon B., Peterson Marnie L., Kranz D.M., Schlievert Patrick M. Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. Clin. Infect. Dis. 2009, 49:1893-1896.
18. Pinna G.S., Kafetzis D.A., Tselkas O.I., Skevaki C.L. Kawasaki disease: an overview. Curr. Opin. Infect. Dis. 2008, 21:263-270.
19. Takahashi N., Nishida H., Kato H., Imanishi K., Sakata Y., Uchiyama T. Exanthematous disease induced by toxic shock syndrome toxin 1 in the early neonatal period. The Lancet 1998, 351:1614-1619.
20. MacIsaac C.M., Curtis N., Cade J., Visvanathan K. Superantigens in sepsis. International Congress Series 2006, 1289:121-124.
21. Chan J.D., Pham T.N., Wong J., Hessel M., Cuschieri J., Neff M., Dellit T.H. Clinical outcomes of linezolid vs vancomycin in methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia: retrospective analysis. J. Intensive Care Med. 2011, 26:385-391.
22. Madsen J.M. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin. Lab. Med. 2001, 21:593-605.
23. Mattix M.E., Hunt R.E., Wilhelmsen C.L., Johnson A.J., Baze W.B. Aerosolized staphylococcal enterotoxin B-induced pulmonary lesions in rhesus monkeys (macaca mulatta). Toxicol. Pathol. 1995, 23:262-268.
24. Goto T., Kino T., Hatanaka H., Nishiyama M., Okuhara M., Kohsaka M., Aoki H., Imanaka H. Discovery of fk-506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant. Proc. 1987, 19:4-8.
25. Macian F. Nfat proteins: key regulators of t-cell development and function. Nat. Rev. Immunol. 2005, 5:472-484.
26. Kiani A., Rao A., Aramburu J. Manipulating immune responses with immunosuppressive agents that target nfat. Immunity 2000, 12:359-372.
27. El-Batawy M.M.Y., Bosseila M.A.W., Mashaly H.M., Hafez V.S.G.A. Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis. J. Dermatol. Sci. 2009, 54:76-87.
28. DaSilva L., Welcher B.C., Ulrich R.G., Aman M.J., David C.S., Bavari S. Humanlike immune response of human leukocyte antigen-dr3 transgenic mice to staphylococcal enterotoxins: a novel model for superantigen vaccines. J. Infect. Dis. 2002, 185:1754-1760.
29. Sriskandan S., Unnikrishnan M., Krausz T., Dewchand H., Van Noorden S., Cohen J., Altmann D.M. Enhanced susceptibility to superantigen-associated streptococcal sepsis in human leukocyte antigen-dq transgenic mice. J. Infect. Dis. 2001, 184:166-173.
30. Rajagopalan G., Sen M., David C.S. In vitro and in vivo evaluation of staphylococcal superantigen peptide antagonisits. Infect. Immun. 2004, 72:6733-6737.
31. Tilahun A.Y., Holz M., Wu T.-T., David C.S., Rajagopalan G. Interferon gamma-dependent intestinal pathology contributes to the lethality in bacterial superantigen-induced toxic shock syndrome. PLoS ONE 2011, 6:e16764.
32. Tilahun A.Y., Marietta E.V., Wu T.-T., Patel R., David C.S., Rajagopalan G. Human leukocyte antigen class ii transgenic mouse model unmasks the significant extrahepatic pathology in toxic shock syndrome. Am. J. Pathol. 2011, 178:2760-2773.
33. Rajagopalan G., Sen M., Singh M., Murali N., Nath K.A., Iijima K., Kita H., Leontovich A.A., Unnikrishnan G., Patel R., David C.S. Intranasal exposure to staphylococcal enterotoxin b elicits an acute systemic inflammatory response. Shock 2006, 25:647-656.
34. Busse M., Traeger T., Potschke C., Billing A., Dummer A., Friebe E., Kiank C., Grunwald U., Jack R.S., Schutt C., Heidecke C.-D., Maier S., Broker B.M. Detrimental role for cd4+ t lymphocytes in murine diffuse peritonitis due to inhibition of local bacterial elimination. Gut 2008, 57:188-195.
35. Wang Q., Fang C.H., Hasselgren P.-O. Intestinal permeability is reduced and il-10 levels are increased in septic il-6 knockout mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001, 281:R1013-R1023.
36. Piper K.E., Rouse M.S., Steckelberg J.M., Wilson W.R., Patel R. Ketolide treatment of haemophilus influenzae experimental pneumonia. Antimicrob. Agents Chemother. 1999, 43:708-710.
37. Ulrich R., Sidell S., Taylor T.J., Wilhelmsen C.L., Franz D.R. Staphylococcal enterotoxin b and related pyrogenic toxins. Text Book of Military Medicine 1997, 621-630. Office of the Surgeon General, Department of Army, United States of America, Bethesda, MD. R. Zajtchuk (Ed.).
38. Wisplinghoff H., Bischoff T., Tallent Sandra M., Seifert H., Wenzel Richard P., Edmond Michael B. Nosocomial bloodstream infections in us hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004, 39:309-317.
39. Tilahun A.Y., Theuer J.E., Patel R., David C.S., Rajagopalan G. Detrimental effect of the proteasome inhibitor, bortezomib in bacterial superantigen- and lipopolysaccharide-induced systemic inflammation. Mol. Ther. 2010, 18:1143-1154.
40. Faulkner L., Cooper A., Fantino C., Altmann D.M., Sriskandan S. The mechanism of superantigen-mediated toxic shock: not a simple th1 cytokine storm. J. Immunol. 2005, 175:6870-6877.
41. Rajagopalan G., Polich G., Sen M.M., Singh M., Epstein B.E., Lytle A.K., Rouse M.S., Patel R., David C.S. Evaluating the role of hla-dq polymorphisms on immune response to bacterial superantigens using transgenic mice. Tissue Antigens 2008, 71:135-145.
42. Hauk P.J., Leung D.Y. Tacrolimus (fk506): new treatment approach in superantigen-associated diseases like atopic dermatitis?. J. Allergy Clin. Immunol. 2001, 107:391-392.
43. Kundig T.M., Schorle H., Bachmann M.F., Hengartner H., Zinkernagel R.M., Horak I. Immune responses in interleukin-2-deficient mice. Science 1993, 262:1059-1061.
44. Kneitz B., Herrmann T., Yonehara S., Schimpl A. Normal clonal expansion but impaired fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 1995, 25:2572-2577.
45. Sadlack B., Lohler J., Schorle H., Klebb G., Haber H., Sickel E., Noelle R.J., Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of cd4+ t cells. Eur. J. Immunol. 1995, 25:3053-3059.
46. Chelmicka-Schorr E., Wiegmann K., Wollmann R., Arnason B.G., Kim D.H. Immunoaugmenting effect of fk 506 on experimental allergic encephalomyelitis in lewis rats. J. Autoimmun. 1998, 11:329-334.
47. Shibutani S., Inoue F., Aramaki O., Akiyama Y., Matsumoto K., Shimazu M., Kitajima M., Ikeda Y., Shirasugi N., Niimi M. Effects of immunosuppressants on induction of regulatory cells after intratracheal delivery of alloantigen. Transplantation 2005, 79:904-913.
48. L.A. Edwards, C. O'Neill, M.A. Furman, S. Hicks, F. Torrente, M. Pérez-Machado, E.M. Wellington, A.D. Phillips, S.H. Murch, Enterotoxin-producing staphylococci cause intestinal inflammation by a combination of direct epithelial cytopathy and superantigen-mediated t-cell activation, Inflamm. Bowel Dis. doi:10.1002/ibd.21852.
49. Campbell W.N., Fitzpatrick M., Ding X., Jett M., Gemski P., Goldblum S.E. Seb is cytotoxic and alters ec barrier function through protein tyrosine phosphorylation in vitro. Am. J. Physiol. Lung Cell. Mol. Physiol. 1997, 273:L31-L39.